IL2 and prostate cancer: The aim of this study was to compare and contrast the influence of CTV-1 priming and IL-2 activation of NK cells, an approach which has been shown to have immunotherapeutic potential in a number of settings (14, 15), from patients with prostate cancer on their ability to kill the NK cell-resistant cell line PC3 which is considered to represent an aggressive form of metastatic prostate cancer (32).